Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.
Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...
On Thursday, Human Genome Sciences HGSI announced full positive Phase IIb Albuferon trial results from a study done on genotype 1 hepatitis C patients. We are maintaining our fair value estimate as we had already assigned a success rate for Albuferon equivalent to a Phase III drug when interim data ...
We dive into the process for adding companies and booting them from the iconic index.
StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.
This screen finds companies ready to take advantage when major provisions of law take effect in 2014.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
Week ending Oct. 27: Stocks held in check by jump oil prices, weak housing market.
The broad stock runup in the first half of 2013 was a boon to ClearBridge Aggressive Growth, and comanager Evan Bauman says that the fund is well-positioned for the market going forward.